Ibezapolstat is poorly absorbed and apparently nontoxic in the hamster C. difficile-associated disease (CDAD) model (potential for achieving a high local concentration at the site of C. difficile infection in the colon). Ibezapolstat (50 mg/kg; p.o.; twice daily; for 3 days) shows strong anti-C. difficile properties in the hamster CDAD model.